Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Oral nimodipine is administered to improve clinical outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). In this study, clinical outcome in patients with and without oral nimodipine administration was assessed.
Materials And Methods: A total of 105 patients did not receive oral nimodipine but did receive intra-arterial nimodipine in the occurrence of hemodynamically relevant vasospasm after aSAH, whereas 74 patients received applications of both. Demographic/radiological details and clinical presentation were abstracted from the case records.
Results: Patient baseline characteristics were comparable, a predominance of endovascular coiling was shown in cohort 2 (p=0.0135). Severity of initial aSAH and clinical status at admission (Hunt and Hess) was significantly higher in those receiving oral nimodipine. Incidence of angiographic vasospasm was significantly higher in patients not treated with oral nimodipine (p=0.0305); a significantly better outcome measured by the National Institute of Health Stroke Scale (p=0.0213), was noted in those receiving oral nimodipine.
Conclusion: Oral nimodipine administration improved clinical outcome of patients after aSAH and should be administered routinely for such patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899118 | PMC |
| http://dx.doi.org/10.21873/invivo.11692 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preparation, Characterization and Drug Release Properties of 5-(p-Carboxyphenoxy) valeric Anhydride Microspheres Loaded with Nimodipine.
Pharm Dev Technol
September 2025
School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, wenhua Road 103, Shenyang 110016, PR China.
Nimodipine (NMP), a poorly water-soluble small-molecule agent, demonstrates notable therapeutic limitations in addressing cerebral vasospasm secondary to subarachnoid hemorrhage (SAH). Owing to its inherent physicochemical properties characterized by low oral bioavailability, rapid elimination half-life, and extensive first-pass metabolism, conventional formulations necessitate frequent dosing regimens to sustain therapeutic plasma concentrations. These pharmacological challenges collectively result in suboptimal patient adherence, marked plasma concentration fluctuations, and recurrent vascular irritation.
View Article and Find Full Text PDFProlonged and recurrent reversible cerebral vasoconstriction syndrome in the postpartum period.
Pract Neurol
August 2025
Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Reversible cerebral vasoconstriction syndrome (RCVS) can develop in the early postpartum period and generally has a good prognosis. A 35-year-old woman developed postpartum RCVS, which had started as severe headache after a blood transfusion; a diagnostic cerebral angiogram showed diffuse vasospasm of intracranial vessels. Her clinical course was complicated by subarachnoid haemorrhage, strokes, seizure and recurrent vasospasm, which lasted for 4 weeks.
View Article and Find Full Text PDFDoes duration of nimodipine therapy impact outcome in aneurysmal subarachnoid hemorrhage: systematic review and meta-analysis.
Neurosurg Rev
June 2025
Department of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.
Aneurysmal subarachnoid hemorrhage (aSAH) is a neurosurgical emergency with high morbidity and mortality risks. Vasospasm, a severe subacute complication, may be mitigated by nimodipine, a calcium channel blocker. The optimal duration of nimodipine therapy remains uncertain.
View Article and Find Full Text PDFEarly nimodipine treatment in reversible cerebral vasoconstriction syndrome: A serial transcranial Doppler study.
Headache
June 2025
Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Objectives/background: Although nimodipine is commonly used to treat reversible cerebral vasoconstriction syndrome (RCVS), its disease-modifying effects are not yet understood. We prospectively investigated the effect of nimodipine and treatment initiation timing on the prevention of worsened vasoconstriction in patients with angiogram-proven RCVS.
Methods: In this prospective cohort study, we recruited patients with angiogram-proven RCVS who visited a single headache clinic between June 2019 and November 2021.
Efficacy of Concurrent Utilization of Mannitol and Nimodipine in Treating Hypertensive Intracerebral Hemorrhage and Its Effects on Neurological Function.
Psychiatry Clin Psychopharmacol
June 2025
Department of Neurosurgery, Wujin Hospital Affiliated With Jiangsu University, Changzhou, China.
Background: The goal of this study was to retrospectively appraise the efficacy of the combined therapy comprising mannitol and nimodipine for hypertensive intracerebral hemorrhage (HICH) and its impact on neurological function.
Methods: The study subjects encompassed 100 individuals with HICH who were admitted to the hospital from May 2021 to 2023 and were categorized into a control group and an observation group, with 50 individuals comprising each group. Intravenous mannitol infusion was administered to the control group, while the observation group received nimodipine injection in combination with mannitol, followed by a course of oral nimodipine tablets.